PROSPECTIVE STUDY OF PERIPHERAL PANRETINAL PHOTOCOAGULATION OF AREAS OF NONPERFUSION IN CENTRAL RETINAL VEIN OCCLUSION
- 1 January 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (1) , 56-62
Abstract
Purpose: To investigate the effect that panretinal photocoagulation to peripheral areas of retinal vascular nonperfusion has on the visual acuity and injection frequency of ranibizumab in eyes with previous central retinal vein occlusion. Methods: Patients enrolled in a prospective study of ranibizumab for central retinal vein occlusion were imaged with wide-field angiography using the Optos P200 system. Laser photocoagulation was carried out and the extent of laser photocoagulation was evaluated with repeat wide-field angiography. Injection of ranibizumab was based on an as needed strategy throughout the study. The injection frequency in the 6 months before laser was compared with a 6-month period starting 2 months after the laser photocoagulation. The visual acuity was measured by Early Treatment Diabetic Retinopathy Study protocol refraction at both the end of the 6-month follow-up period and at the time of laser photocoagulation. Results: There were 10 patients treated in this study with a mean number of 1,757 spots of laser photocoagulation in the peripheral retina. The injection frequency in the 6-month lead-in period was 3.4 and in the 6-month follow-up period was 3.1, a difference that was not significant (P = 0.26). The visual acuity at the time of laser photocoagulation was 54.2 letters (approximate Snellen equivalent of 20/80) and at the end of the observation period was 51.4 letters, a difference that was not significant (P = 0.33). Conclusion: In this small study, laser photocoagulation to peripheral areas of nonperfusion as visualized by wide-field angiography did not result in either decreased injection frequency or improved visual acuity in eyes with central retinal vein occlusion treated with ranibizumab.Keywords
This publication has 34 references indexed in Scilit:
- Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical StimulatorMolecular Therapy, 2008
- Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT studyDocumenta Ophthalmologica, 2008
- Early Bevacizumab Treatment of Central Retinal Vein OcclusionAmerican Journal of Ophthalmology, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) IN CENTRAL RETINAL VEIN OCCLUSIONRetina, 2007
- INTRAVITREAL BEVACIZUMAB INJECTIONS FOR TREATMENT OF CENTRAL RETINAL VEIN OCCLUSIONRetina, 2007
- Bevacizumab in retinal vein occlusion-results of a prospective case seriesGraefe's Archive for Clinical and Experimental Ophthalmology, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR CENTRAL AND HEMICENTRAL RETINAL VEIN OCCLUSIONSRetina, 2007
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSIONRetina, 2006
- Intravitreal Bevacizumab for Choroidal Neovascularization and Cystoid Macular Edema: A Cost-Effective Treatment?Ophthalmic Surgery, Lasers and Imaging Retina, 2005
- Correlation of Increased Vascular Endothelial Growth Factor With Neovascularization and Permeability in Ischemic Central Vein OcclusionArchives of Ophthalmology (1950), 2002